Angelos Evangelopoulos

Dr. Angelos Evangelopoulos

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
Natalia G. VallianouNatalia G. Vallianou
Natalia G. Vallianou
DKDimitris Kounatidis
Dimitris Kounatidis
DTDimitrios Tsilingiris
Dimitrios Tsilingiris
FPFotis Panagopoulos
Fotis Panagopoulos
GCGerasimos Socrates Christodoulatos
Gerasimos Socrates Christodoulatos
MDMaria Dalamaga
Maria Dalamaga
Obesity and obesity-associated disorders pose a major public health issue worldwide. Apart from conventional weight loss drugs, next-generation probiotics (NGPs) seem to be very promising as potential preventive and therapeutic agents against obesity. Candidate NGPs such as Akkermansia muciniphila, Faecalibacterium prausnitzii, Anaerobutyricum hallii, Bacteroides uniformis, Bacteroides coprocola, Parabacteroides distasonis, Parabacteroides goldsteinii, Hafnia alvei, Odoribacter laneus and Christensenella minuta have shown promise in preclinical models of obesity and obesity-associated disorders. Proposed mechanisms include the modulation of gut flora and amelioration of intestinal dysbiosis, improvement of intestinal barrier function, reduction in chronic low-grade inflammation and modulation of gut peptide secretion. Akkermansia muciniphila and Hafnia alvei have already been administered in overweight/obese patients with encouraging results. However, safety issues and strict regulations should be constantly implemented and updated. In this review, we aim to explore (1) current knowledge regarding NGPs; (2) their utility in obesity and obesity-associated disorders; (3) their safety profile; and (4) their therapeutic potential in individuals with overweight/obesity. More large-scale, multicentric and longitudinal studies are mandatory to explore their preventive and therapeutic potential against obesity and its related disorders.

12 February 2024 in Metabolites
Verified
Journal Article
Open access
PDF file
DKDimitris Kounatidis
Dimitris Kounatidis
Natalia G. VallianouNatalia G. Vallianou
Natalia G. Vallianou
APAikaterini Poulaki
Aikaterini Poulaki
AEAngelos Evangelopoulos
Angelos Evangelopoulos
FPFotis Panagopoulos
Fotis Panagopoulos
MDMaria Dalamaga
Maria Dalamaga
ApoB is the main protein of triglyceride-rich lipoproteins and is further divided into ApoB48 in the intestine and ApoB100 in the liver. Very low-density lipoprotein (VLDL) is produced by the liver, contains ApoB100, and is metabolized into its remnants, intermediate-density lipoprotein (IDL) and low-density lipoprotein (LDL). ApoB100 has been suggested to play a crucial role in the formation of the atherogenic plaque. Apart from being a biomarker of atherosclerosis, ApoB100 seems to be implicated in the inflammatory process of atherosclerosis per se. In this review, we will focus on the structure, the metabolism, and the function of ApoB100, as well as its role as a predictor biomarker of cardiovascular risk. Moreover, we will elaborate upon the molecular mechanisms regarding the pathophysiology of atherosclerosis, and we will discuss the disorders associated with the APOB gene mutations, and the potential role of various drugs as therapeutic targets.

13 May 2023 in Nutrients
Verified
Journal Article
Open access
PDF file
DKDimitris Kounatidis
Dimitris Kounatidis
Natalia G. VallianouNatalia G. Vallianou
Natalia G. Vallianou
AEAngelos Evangelopoulos
Angelos Evangelopoulos
IVIoannis Vlahodimitris
Ioannis Vlahodimitris
EGEugenia Grivakou
Eugenia Grivakou
IMIordanis Mourouzis
Iordanis Mourouzis
The nucleotide-binding domain-like receptor protein 3 (NLRP3) inflammasome in the kidney and the heart is increasingly being suggested to play a key role in mediating inflammation. In the kidney, NLRP3 activation was associated with the progression of diabetic kidney disease. In the heart, activation of the NLRP3 inflammasome was related to the enhanced release of interleukin-1β (IL-1β) and the subsequent induction of atherosclerosis and heart failure. Apart from their glucose-lowering effects, SGLT-2 inhibitors were documented to attenuate activation of the NLRP3, thus resulting in the constellation of an anti-inflammatory milieu. In this review, we focus on the interplay between SGLT-2 inhibitors and the inflammasome in the kidney, the heart and the neurons in the context of diabetes mellitus and its complications.

18 October 2024 in Diagnostics
Verified
Journal Article
Open access
PDF file
Eleni V. GeladariEleni V. Geladari
Eleni V. Geladari
Natalia G. VallianouNatalia G. Vallianou
Natalia G. Vallianou
AEAngelos Evangelopoulos
Angelos Evangelopoulos
PKPetros Koufopoulos
Petros Koufopoulos
FPFotis Panagopoulos
Fotis Panagopoulos
CGCharalampia V. Geladari
Charalampia V. Geladari
Kidney disease is linked to the development of cardiovascular disorders, further increasing morbidity and mortality in this high-risk population. Thus, early detection of myocardial damage is imperative in order to prevent devastating cardiovascular complications within this patient group. Over the years, cardiac biomarkers have been identified and are now widely used in everyday clinical practice. More specifically, available data suggest that cardiac troponin and its regulatory subunits (TnT, TnI, and TnC) reflect the injury and necrosis of myocardial tissue. While cTnC is identical in cardiac and skeletal muscle, TnT and TnI constitute cardiac-specific forms of troponin, and, as such, they have been established by international societies as biomarkers of cardiac damage and diagnostic indicators for acute myocardial infarction. Elevations in the levels of both cardiac troponins (cTnT and cTnI) have been also reported in asymptomatic patients suffering from chronic kidney disease. Therefore, if abnormal, they often generate confusion among clinicians regarding the interpretation and clinical significance of their numerical values in emergency settings. The aim of this review is to explore the reasons behind elevated troponin levels in patients with chronic kidney disease and identify when these elevated levels of biomarkers indicate the need for urgent intervention, considering the high cardiovascular risk in this patient group.

18 April 2023 in Preprints.org
Verified
Preprint
Open access
PDF file
DKDimitris Kounatidis
Dimitris Kounatidis
Natalia G. VallianouNatalia G. Vallianou
Natalia G. Vallianou
AEAngelos Evangelopoulos
Angelos Evangelopoulos
IVIoannis Vlachodimitris
Ioannis Vlachodimitris
EGEugenia Grivakou
Eugenia Grivakou
IMIordanis Mourouzis
Iordanis Mourouzis
Nucleotide-binding domain like receptor protein 3 (NLRP3) inflammasome in the kidney and the heart is increasingly being suggested to play a key role in mediating inflammation. In the kidney, NLRP3 activation has been associated with the progression of diabetic kidney disease. In the heart, activation of the NLRP3 inflammasome has been related to enhanced release of interleukin-1β (IL-1β) and the subsequent induction of atherosclerosis and heart failure. Apart from their glucose-lowering effects, SGLT-2 Inhibitors have been documented to attenuate activation of the NLRP3, thus, resulting in the constellation of an anti-inflammatory milieu. In this review, we will focus on the interplay between SGLT-2 Inhibitors and the inflammasome in the kidney, the heart and the neurons in the context of diabetes mellitus and its complications.

19 February 2025 in Biomolecules
Verified
Journal Article
Open access
PDF file
Natalia G. VallianouNatalia G. Vallianou
Natalia G. Vallianou
AEAngelos Evangelopoulos
Angelos Evangelopoulos
ITIlektra Tzivaki
Ilektra Tzivaki
SDSTAVROULA DASKALOPOULOU
STAVROULA DASKALOPOULOU
AAAndreas Adamou
Andreas Adamou
DKDimitris Kounatidis
Dimitris Kounatidis
Ultra-processed foods (UPFs) are foods that have undergone extensive industrial processing with the addition of various substances in order to make them more tasty, eye-catching, and easy to consume. UPFs are usually rich in sugars, salt, and saturated fat, whereas they lack essential nutrients. The aim of this review is to elaborate upon the current evidence associating overconsumption of UPFs with the development of type 2 diabetes mellitus (T2DM). We will discuss data interconnecting UPFs and T2DM risk and will further describe specific ingredients that have been suggested to increase this risk. In addition, we will thoroughly explain how additives, such as emulsifiers or sweeteners, or other compounds formed during manufacturing, such as acrylamide and acrolein, and during packaging, such as bisphenol-A, are proposed to be implicated in the pathogenesis of insulin resistance and T2DM.